Pulmonary fibrosis causes progressive lung scarring, making breathing difficult and limiting daily activities. For years, only two medications—pirfenidone and nintedanib—were available, offering limited relief by slowing disease progression. Now, clinical trials are testing promising new treatments that may further slow the disease, reduce side effects, and even repair lung damage. https://froodl.com/new-breakthroughs-emerging-from-pulmonary-fibrosis-clinical-trials